SCHEMBL9830660

SCHEMBL9830660

COc1ccccc1C(=O)N[C@H](C(=O)O)C(C)C

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.67
ALDH1A1 P00352 3/20 0.67
L3MBTL1 Q9Y468 1/20 0.56
KCNA3 P22001 1/20 0.56
CTSD P07339 1/20 0.55
RAB9A P51151 4/20 0.55
NPC1 O15118 3/20 0.55
MAPT P10636 3/20 0.53
STAT3 P40763 1/20 0.53
TP53 P04637 1/20 0.52
GLA P06280 1/20 0.52
USP2 O75604 1/20 0.52
KCNK3 O14649 2/20 0.50
KCNK9 Q9NPC2 2/20 0.50
TSHR P16473 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
KMT2A Q03164 1/20 0.49
GAA P10253 1/20 0.49
MAPK1 P28482 1/20 0.49
HSD17B10 Q99714 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9830652 1.00 HPGD (0.67) HPGDALDH1A1L3MBTL1KCNA3CTSD
SCHEMBL17402210 0.90 HPGD (0.65) HPGDALDH1A1L3MBTL1KCNA3CTSD
SCHEMBL17402212 0.90 HPGD (0.65) HPGDALDH1A1L3MBTL1KCNA3CTSD
SCHEMBL3598204 0.86 HPGD (0.60) HPGDALDH1A1L3MBTL1KCNA3CTSD
SCHEMBL21274442 0.86 HPGD (0.60) HPGDALDH1A1L3MBTL1KCNA3CTSD
SCHEMBL21274439 0.86 HPGD (0.60) HPGDALDH1A1L3MBTL1KCNA3CTSD
SCHEMBL3857142 0.85 HPGD (0.61) HPGDALDH1A1RAB9ANPC1MAPT
SCHEMBL11509066 0.85 RAB9A (0.53) HPGDALDH1A1L3MBTL1RAB9AMAPT
SCHEMBL2251629 0.84 HPGD (0.70) HPGDALDH1A1L3MBTL1KCNA3CTSD
SCHEMBL2792267 0.84 HPGD (0.70) HPGDALDH1A1L3MBTL1KCNA3CTSD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230257388-A1 GRANZYME B DIRECTED IMAGING AND THERAPY CYTOSITE BIOPHARMA INC. (US) 2023-08-17 US disclosed
US-11667645-B2 Granzyme B directed imaging and therapy CYTOSITE BIOPHARMA INC. (US) 2023-06-06 US disclosed
CN-112261939-A Granzyme B directed imaging and therapy 塞托赛特生物制药股份有限公司 2021-01-22 CN disclosed
US-20200369673-A1 GRANZYME B DIRECTED IMAGING AND THERAPY CYTOSITE BIOPHARMA INC. 2020-11-26 US disclosed
EP-0226304-B1 COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC SANKYO COMPANY LIMITED (JP) 1991-08-28 EP disclosed
US-4757066-A Reduces renal toxicity SANKYO COMPANY LIMITED (JP) 1988-07-12 US disclosed
EP-0226304-A1 Composition containing a penem or carbapenem antibiotic SANKYO COMPANY LIMITED (JP) 1987-06-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257388-A1 GRANZYME B DIRECTED IMAGING AND THERAPY GZMB, PRF1, CTSB HPGD 1240/4885ALDH1A1 4592/4885L3MBTL1 1904/4885
US-20200369673-A1 GRANZYME B DIRECTED IMAGING AND THERAPY GZMB, PRF1, CTSB HPGD 1240/4885ALDH1A1 4592/4885L3MBTL1 1904/4885
US-11667645-B2 Granzyme B directed imaging and therapy GZMB, PRF1, CTSB HPGD 1240/4885ALDH1A1 4592/4885L3MBTL1 1904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.